The Hepatitis A drugs in development market research report provides comprehensive information on the therapeutics under development for Hepatitis A, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hepatitis A. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hepatitis A and features dormant and discontinued products.

GlobalData tracks ten drugs in development for Hepatitis A by ten companies/universities/institutes. The top development phase for Hepatitis A is preclinical with four drugs in that stage. The Hepatitis A pipeline has ten drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Hepatitis A pipeline products market are: Indian Immunologicals, Liaoning Cheng Da Biotechnology and Suzhou Ribo Life Sciences.

The key targets in the Hepatitis A pipeline products market include Terminal Nucleotidyltransferase 4A (Non Canonical Poly(A) RNA Polymerase PAPD7 or PAP Associated Domain Containing Protein 7 or TENT4A or EC 2.7.7.19), and Terminal Nucleotidyltransferase 4B (Non canonical Poly(A) RNA Polymerase PAPD5 or PAP-Associated Domain Containing Protein 5 or Terminal Guanylyltransferase or PAPD5 or TENT4B or EC 2.7.7.19).

The key mechanisms of action in the Hepatitis A pipeline product include Terminal Nucleotidyltransferase 4B (Non canonical Poly(A) RNA Polymerase PAPD5 or PAP-Associated Domain Containing Protein 5 or Terminal Guanylyltransferase or PAPD5 or TENT4B or EC 2.7.7.19) Inhibitor with one drug in Preclinical. The Hepatitis A pipeline products include two routes of administration with the top ROA being Intramuscular and five key molecule types in the Hepatitis A pipeline products market including Inactivated Vaccine, and Small Molecule.

Hepatitis A overview

Hepatitis A is inflammation of the liver caused bythe hepatitis A virus. Symptoms include fatigue, nausea and vomiting, inflammation of the liver, loss of appetite, dark urine, muscle pain, and yellowing of the skin and eyes (jaundice). Risk factors include weakened immune system and use of injected or non-injected illicit drugs. Treatment includes antiemetics and pain relievers.

For a complete picture of Hepatitis A’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.